Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.55 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3342876 | 0.98 | GAA (0.96) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| Morpholine SCHEMBL3636258 | 0.83 | GFER (0.69) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL3344780 | 0.78 | GAA (0.64) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL15568639 | 0.78 | HDAC8 (1.00) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL3342194 | 0.78 | KDM4E (0.64) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL3343853 | 0.78 | GFER (0.64) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL3343038 | 0.78 | GFER (0.64) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL638903 | 0.77 | KDM4E (0.61) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL3344186 | 0.77 | KDM4E (0.61) | GAAGFERKDM4EHDAC8ALDH1A1 | |
| SCHEMBL3341447 | 0.77 | KDM4E (0.61) | GAAGFERKDM4EHDAC8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE | 2010-06-24 | — | — | US | claimed |
| EP-2164486-A2 | USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS | Galderma Research & Development (FR) | 2010-03-24 | — | — | EP | claimed |
| WO-2008152330-A2 | USE OF 4-PHENYL-IMIDAZOLE-2-THIONES AS TYROSINASE INHIBITORS FOR PREPARING PHARMACEUTICAL OR COSMETIC COMPOSITIONS FOR TREATING OR PREVENTING PIGMENT DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | claimed |
| US-9592230-B2 | Substituted imidazoles as PDE10A inhibitors | H. LUNDBECK A/S (DK) | 2017-03-14 | — | — | US | disclosed |
| US-20150190395-A1 | Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors | H. LUNDBECK A/S (DK) | 2015-07-09 | — | — | US | disclosed |
| US-9018217-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-04-28 | — | — | US | disclosed |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2015-01-22 | — | — | US | disclosed |
| US-8865711-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2014-10-21 | — | — | US | disclosed |
| EP-2318394-B1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-05-31 | — | — | US | disclosed |
| US-8133897-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-4912226-A | A 1-(benyzlsubstituted-),2-((1,3-dioneisoindolin-2-yl)alkyl thio-)imidazole | SMITHKLINE BECKMAN CORPORATION (US) | 1990-03-27 | — | — | US | disclosed |
| US-4882348-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-11-21 | — | — | US | disclosed |
| EP-0170775-B1 | DERIVATIVES OF BICYCLIC AMINO ACIDS, PROCESSES FOR THEIR PREPARATION, AGENTS CONTAINING THEM AND THEIR USE AS WELL AS BICYCLIC AMINO ACIDS AS INTERMEDIATES AND PROCESS FOR THEIR PREPARATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-11-08 | — | — | EP | disclosed |
| WO-1989006127-A1 | 2-AMINOALKYLTHIOIMIDAZOLES AS DOPAMINE-beta-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-07-13 | — | — | WO | disclosed |
| WO-1989006128-A1 | 2-CARBOXYALKYLTHIOIMIDAZOLES AND ESTERS THEREOF AS DOPAMINE-beta-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0323148-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-07-05 | — | — | EP | disclosed |
| EP-0323146-A2 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-07-05 | — | — | EP | disclosed |
| EP-0302603-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4798843-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | TYR, TH, PAH | GAA 58/4885GFER 2509/4885KDM4E 1018/4885 |
| US-20150190395-A1 | Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors | PDE10A, PDE5A, PDE3B | GAA 32/4885GFER 4049/4885KDM4E 356/4885 |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | GAA 32/4885GFER 4049/4885KDM4E 356/4885 |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | GAA 32/4885GFER 4049/4885KDM4E 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.